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Tocotrienols (T3) are well-known for their antioxidant properties besides showing
therapeutic potential in clinical complications such as hyperlipidemia induced by
diabetes. The aim of this study was to determine the effects of δ-T3, γ-T3, and α-T3
on insulin secretion-associated genes expression of rat pancreatic islets in a dynamic
culture. Pancreatic islets freshly isolated from male Wistar rats were treated with T3
for 1 h at 37◦C in a microfluidic system with continuous operation. The cells were
collected for total RNA extraction and reverse-transcribed, followed by measurement of
insulin secretion-associated genes expression using quantitative real-time polymerase
chain reaction. Molecular docking experiments were performed to gain insights on
how the T3 bind to the receptors. Short-term exposure of δ- and γ-T3 to pancreatic
β cells in a stimulant glucose condition (16.7 mM) significantly regulated preproinsulin
mRNA levels and insulin gene transcription. In contrast, α-T3 possessed less ability in
the activation of insulin synthesis level. Essentially, potassium chloride (KCl), a β cell
membrane depolarising agent added into the treatment further enhanced the insulin
production. δ- and γ-T3 revealed significantly higher quantitative expression in most
of the insulin secretion-associated genes groups containing 16.7 mM glucose alone
and 16.7 mM glucose with 30 mM KCl ranging from 600 to 1200 µM (p < 0.05).
The findings suggest the potential of δ-T3 in regulating insulin synthesis and glucose-
stimulated insulin secretion through triggering pathway especially in the presence of
KCl.
Keywords: tocotrienols, insulin, microfluidic system, gene expression profiling, qRT-PCR, molecular docking
INTRODUCTION
Insulin is the most potent anabolic hormone secreted by the pancreatic islets of Langerhans
of β cell. Insulin functions as a glucose homeostasis regulator in the regulation of insulin
gene transcription and translation, preproinsulin mRNA stability control and insulin secretion
(Shulman, 2000; Ren et al., 2007). Failure of the body to produce or response to insulin
leads to the development of diabetes mellitus. The chronic complications of diabetes mellitus
lead to a progressive deterioration in the function of pancreatic β cell and development of
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hyperglycemia (Bösenberg and van Zyl, 2008) with long-term
clinical problems and onset of chronic complications (Niu
et al., 2008). Recently, tocotrienols (T3) have been actively
investigated due to their therapeutic impacts toward the
secondary complications of diabetes mellitus.
Tocotrienols (T3) are naturally occurring derivatives
belonging to the vitamin E family synthesized by plants. α-,
δ-, and γ-T3 are members of the four unsaturated analogs of
vitamin E (Aggarwal et al., 2010). The chemical structures of
T3 are slightly different from tocopherols, another category of
vitamin E, in the degree of saturation in their farnesyl side chain
at the C-2 position. T3 consist of lipid-soluble farnesyl side-chain
that provides the added advantage for the differential membrane
distribution and metabolism of T3 as compared to tocopherols
(Theriault et al., 1999; Vignini et al., 2011). In contrast to their
structural similarity, the methyl group position determines
the individual compound (Figure 1) (Passwater, 2012). The
unsaturated chain of T3 is able to penetrate into saturated fatty
layer tissues as a significant level of T3 was detected in the
brain and liver (Passwater, 2012; Ahsan et al., 2014). Studies
had proven that T3 also functioned as signaling molecule in
antioxidant properties with α-T3 having 40–60 times more
potent antioxidative protection than α-tocopherol in rat liver
lipid (Serbinova et al., 1991; Tan, 2005).
The introduction of microfluidic technology in cell culture
and pharmaceutical industries provided a platform to greatly
improved throughput as well as eliminating the limitations of
cell-based studies. A microfluidic device is designed for the long-
term monitoring of the cell culture processes combining the
typical cell culture practices on an independent microfluidic
system. The continuous operation of microfluidic system was able
to maintain a stable cell culture environment, with a platform
for wide-ranging assays (Hung et al., 2005). The cell culture
array offered many potential applications in drug screening,
eliminating the limitations in cell-based drug screening assays
such as high cost of operation as well as allowing the continuous
monitoring of cell culture over long periods of time. The ability of
microfabrication technologies to control cell shape, intracellular
contact and co-culture interactions are aiding the induction of
cells to model their in vivo gene expression and functional states
more faithfully in culture system and drug discovery (Bhadriraju
and Chen, 2002).
FIGURE 1 | Chemical structures of tocotrienol isomers.
While extensive researches has been carried out using
tocotrienol rich fractions (TRFs) and T3 on complications of
diabetes mellitus, putative effects of each single T3 have not
been tested yet on pancreatic β cells. Therefore the present study
was carried out to investigate the effects of T3s (δ-, γ-, and α-)
on insulin secretion-associated genes expression of normal rat
pancreatic islets cultured in glucose and KCl using a microfluidic
system.
MATERIALS AND METHODS
Tocotrienols
δ-Tocotrienol, γ-tocotrienol, and α-tocotrienol were purchased
from Cayman Chemical, i-DNA (M) Sdn. Bhd, Malaysia
(Cayman Chemical, USA). The purity of each T3 was ≥98%.
Animals
Male adult Wistar rats of age more than 12 weeks old,
weight between 300 to 350 g were used in the study. The
rats were purchased from the Laboratory Animal Resource
Unit (LARU) of Universiti Kebangsaan Malaysia (UKM). The
animals were maintained under the guideline of UKM Animal
Ethics Committee (UKMAEC). They were kept under standard
conditions at room temperature with free access to food and
water at all time before use. The use of animals for this
study has been obtained the UKM animal ethnic approval
of FF/2011/IBRAHIM/19-MAY/371-MAY-2011-AUGUST-2013-
AR-CAT2.
Isolation and Culture of Rat Pancreatic
Islets
Rat pancreatic islets isolation was carried out according to
Shewade et al. (1999) with minor modifications. Briefly, the
animals were anesthetised by anesthetic agent, ilium xylazil-
20 (Troy Lab. Pty. Lmt. AUS; 20–40 mg/kg body weight i.v.)
which was purchased from LARU of UKM. The pancreas was
removed out using aseptic technique, and washed with phosphate
buffer saline (PBS; Gibco, Invitrogen, USA) supplemented with
antibiotic antimycotic (AA; Gibco, Invitrogen, USA; 2% v/v).
Next, enzymatic digestion of the pancreas was carried out with
5 mL of cold collagenase V [0.3% w/v collagenase V (Sigma-
Aldrich, St. Louis, MO, USA), 2% v/v AA and 10% v/v fetal bovine
serum (FBS; Gibco, Invitrogen, USA)] in 50 mL conical plastic
tube for 15 min at 37◦C in water bath shaker until completion of
digestion. The digestion was terminated by adding 20 mL of PBS
and centrifuged at 1000 rpm for 10 min. After digestion, the islets
were cultured in supplemented RPMI-1640 (Gibco, Invitrogen,
USA) medium (10% v/v FBS, 1% v/v AA) pH-7.2 in 6-well plate
(2 ml per well) and kept at 37◦C, 5% CO2 incubator (RS biotech,
UK) overnight to allow recovery from the isolation procedure.
Tocotrienol Treatment: Dynamic
Incubation
The islets with oblong to spherical shape, smooth surface and a
diameter of 100–200 µm were used in this treatment. After 24 h
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incubation, groups of 20 islets were handpicked under Nikon
SMZ645 stereomicroscope (Nikon, Japan) and transferred into
the cell culture chambers of Cell AsicTM ONIX microfluidic open
top plate (Merck EMD, Millipore Corporation, USA) containing
350 µl of preincubation medium. The preincubation medium
consisted of Dulbecco’s phosphate-buffered saline (D-PBS; 10%
v/v FBS) with basal 2.8 mM glucose. The microfluidic plate
was attached to Onix Microfluidic Perfusion System and Onix
Microincubator Controller (CellASIC, Millipore Corporation,
USA) with supply of 5% CO2 at 37◦C. The cell culture chambers
were also constantly perfused with preincubation medium
applied with a flow driven by gas pressure system at 4 psi for
30 min establishing basal levels of secretion. Each group of islets
were then treated with 350 µL of different concentrations of
T3s (α, γ, and δ; Cayman Chemical, USA) treatment mediums
that were perfused at 4 psi for 1 h. The final concentrations of
T3s in the treatment mediums (D-PBS with 10% v/v FBS) were
150, 300, 600, and 1200 µM in glucose alone (2.8 and 16.7 mM,
as basal and stimulant, respectively; Wicksteed et al., 2003;
Ronnebaum et al., 2006; Monfared and Pournourmohammadi,
2010) or together with 30 mM KCl (Sato and Henquin, 1998;
Yajima et al., 1999; Shackman et al., 2004). The treated groups
were all compared with their respective positive control group
(1 µM of glyburide; Kinard and Satin, 1995; Wicksteed et al.,
2003) and negative control group (glucose and, or KCl medium
only). The β islets were harvested from cell culture chamber for
total RNA extraction in the gene expression study.
Cell Viability Assay
Cell viability assay was carried out with Alamar Blue cell viability
reagent (Life Technologies, USA) according to the manufacturer’s
standard protocol to assess the survival of treated islets. After
1 h incubation, all T3 treatment groups with 20 islets were
transferred into a 96-wells plate. After that, 10% v/v of 10X
Alamar Blue cell viability reagent was added into each well-
followed by 4 h incubation at 37◦C, 5 % CO2 incubator (RS
biotech, UK). The blue color of resazurin, an active compound
of Alamar Blue reagent was converted to red and highly
fluorescence resorufin by the viable islets. The absorbance of
Alamar Blue was then monitored at 570 nm using 600 nm as
a reference wavelength (normalized to the 600 nm value) with
Monochromator Microplate (Thermo Scientific, USA). Finally
the results were analyzed by plotting absorbance versus T3
concentrations.
Relative Gene Expression Analysis (RNA
Extraction, cDNA Synthesis, Primer
Preparation, and qRT-PCR)
Total RNA Extraction
Total RNA was extracted from the treated islets group
using Tri reagent R© (Molecular Research Center, Cincinnati,
OH, USA) according to the manufacturer’s recommended
protocol. Chloroform was added into the homogenized islets for
phase separation followed by isopropanol (Rankem, USA) and
polyacryl carrier (Molecular Research Center, Cincinnati, OH,
USA) for the precipitation of total RNA forming the RNA pellet.
The pellet was then centrifuged at 12,000 rpm for 8 min at 4◦C
and washed with 75% ethanol (Scharlau, Spain). The pellet was
dried for 20 min before solubilising in DNase and RNase free
distilled water (Gibco, Invitrogen, USA). The extracted RNA was
stored at−80◦C for further analysis.
Reverse Transcription (cDNA Synthesis)
The total RNA was reversed transcribed using SuperScript R© III
(Invitrogen, Life Technologies, USA). cDNA was synthesized
from 5 µl of total RNA and the reaction was performed according
to the manufacturer’s recommended protocol in the following
steps: 10 min at 25◦C, 30 min at 50◦C, 5 min at 85◦C followed
by 20 min at 37◦C. The synthesized cDNA was stored at −20◦C
for further analysis.
Quantitative Real-Time Polymerase Chain Reaction
(qRT-PCR)
The synthesized cDNA was used to perform quantitative
real-time polymerase chain reaction (PCR) using SYBR R©
Select master mix to measure the expression level of the
insulin secretion-associated genes. Peroxisome proliferator-
activated receptors δ (PPARδ), peroxisome proliferator-activated
receptors γ (PPARγ), insulin 1 (INS1), glucose transporter
2 (GLUT2), pancreatic/duodenal homeobox-1 (PDX1), V-maf
musculoaponeurotic fibrosarcoma oncogene homolog (MafA)
and neurogenic differentiation 1 (BETA2) gene expression levels
were assessed. Beta-actin (Actb) was used as the housekeeping
gene to normalize the data. The specific forward and reverse
primers for each gene were designed by using Primer 3 software
based on NIH GeneBank database sequences and synthesized by
Bio Basic Canada, Inc. (Table 1). The PCR reaction was carried
out in My iQ-I cycler (Bio-Rad, USA). The reaction mixture
consisted of SYBR R© Select master mix (Applied biosystem, Life
Technologies, USA), forward and reverse primers (500 nM each),
deionised water and cDNA. The reactions were carried out in
the following parameter: cycle 1: step 1 50◦C for 2 min (1
TABLE 1 | Description of Insulin secretion associated gene primers used
in RT-PCR.
Gene Accession no Primer 5′–3′ PCR product
size (bp)
PPARδ NM_013141.2 R 5′-cagcagtccgtctttgttga-3′
F 5′-gatcagcgtgcatgtgttct-3′
193
PPARγ NM_013124.3 R 5′-gaggccagcatggtgtagat-3′
F 5′-catttttcaagggtgccagt-3′
156
INS1 NM_019129.3 R 5′-ccagttggtagagggagcag-3′
F 5′-gtacctggtgtgtggggaac-3′
200
GLUT2 NM_012879.2 R 5′-cggagaccttctgctcagtc-3′
F 5′-accagctctcctgcagtgtc-3′
191
PDX1 NM_022852.3 R 5′-cgttgtcccgctactacgtt-3′
F 5′-acccgtacagcctacactcg-3′
198
MAF NM_019318.1 R 5′-ctggttcttctccgactcca-3′
F 5′-aaggaggaggtgatccgact-3′
120
BETA2 NM_019218.2 R 5′-tcttgggcttttgatcatcc-3′
F 5′-ttgaagccatgaatgcagag-3′
120
Actb NM_031144.2 R 5′-ctctcagctgtggtggtgaa-3′
F 5′-gtcgtaccactggcattgtg-3′
181
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TABLE 2 | Cell viability (%) after 1 h tocotrienol treatments.
Tocotrienol Tocotrienol concentration
(µM)
2.8 mM glucose 2.8 mM glucose and 30 mM KCl 16.7 mM glucose 16.7 mM glucose and 30 mM KCl
Cell viability (%)
α 150 99.06 97.12 98.4 96.6
300 97.18 97.36 96.88 94.04
600 96.6 93.58 91.49 91.99
1200 94.95 93.77 91.92 90.06
γ 150 98.3 95.5 96.6 97.36
300 98.75 97.4 96.4 90.55
600 95.43 96.3 95.3 92.21
1200 94.5 94.3 94.8 91.67
δ 150 97.76 97.6 96.47 95.41
300 98.3 94.4 94.21 91.35
600 97.43 95.6 94.5 90.65
1200 96.1 93.8 92.21 90.08
FIGURE 2 | The relative gene expression level of PPARδ in α-, γ-, and δ-tocotrienol treatment. (A) 2.8 mM glucose (basal): all α-T3 and δ-T3 groups are 0.01
relative to negative control, all γ-T3 groups are 0.05 relative to negative control, #p < 0.05 relative to 1200 µM (same tocotrienol group). (B) 2.8 mM glucose and
30 mM KCl (calcium raising agent): all α-T3 and δ-T3 groups are 0.05 relative to negative control, 1p < 0.05 relative to negative control. (C) 16.7 mM glucose
(stimulant): all α-T3 are 0.05 relative to negative control, all γ-T3 and δ-T3 groups are 0.01 relative to negative control, #p < 0.05 and ##p < 0.01 relative to 1200 µM
(same tocotrienol group), ∗p < 0.05 and ∗∗p < 0.01 relative to matched group. (D) 16.7 mM glucose and 30 mM KCl: all γ-T3 and δ-T3 groups are 0.05 relative to
negative control, 1p < 0.05 relative to negative control, #p < 0.05 and ##p < 0.01 relative to 1200 µM (same tocotrienol group), ∗p < 0.05 relative to matched group.
time), cycle 2 (activation of Taq DNA polymerase and pre-
denaturation): step 1 95◦C for 2 min (1 time), cycle 3 (PCR
amplification): step 1 (denaturation): 95◦C for 10 s, step 2
(annealing): 56◦C for 20 s and step 3 (extension): 72◦C for
20 s (50 times), cycle 4: step 1 95◦C for 30 s (1 time), cycle
5: 55◦C for 1 min (1 time) and cycle 6: 60◦C for 10 s (70
times). The relative gene expression level of each gene was
obtained by normalizing to Actb. The specificity of the PCR
products were confirmed with melting curve analysis following
the qRT-PCR protocol and further verified by 2% agarose (Gibco,
Invitrogen, USA) gel electrophoresis stained with ethidium
bromide (Sigma-Aldrich, St. Louis, MO, USA) and visualized
by UV transillumination (Vilber Lourmat, Marne La Vallee,
France).
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FIGURE 3 | The relative gene expression level of PPARγ in α-, γ-, and δ-tocotrienol treatment. (A) 2.8 mM glucose: all tocotrienol groups are 0.05 relative to
negative control, #p < 0.05 relative to 1200 µM (same tocotrienol group), ∗∗p < 0.01 relative to matched group. (B) 2.8 mM glucose and 30 mM KCl (calcium
raising agent): 1p < 0.05 and 11p < 0.01 relative to negative control, #p < 0.05 relative to 1200 µM (same tocotrienol group). (C) 16.7 mM glucose (stimulant): all
γ-T3 groups are 0.05 relative to negative control, 1p < 0.05 relative to negative control, #p < 0.05 relative to 1200 µM (same tocotrienol group), ∗p < 0.05 and
∗∗p < 0.01 relative to matched group. (D) 16.7 mM glucose and 30 mM KCl: 1p < 0.05 relative to negative control, @p < 0.05 relative to positive control, #p < 0.05
relative to 1200 µM (same tocotrienol group), ∗p < 0.05 relative to matched group.
Computational Studies
Homology Modeling
The construction of the homology models were initiated with
the searching of rat PPARδ and PPARγ amino acids sequences.
The amino acids sequences of rat PPARδ (Accession Id: Q62879)
and rat PPARγ (Accession Id: O88275) were then retrieved from
UniProtKB (The UniProt Consortium, 2009). BLAST program
was used to search for the suitable template structures in the
Protein Data Bank (PDB) at National Center for Biotechnology
Information, NCBI1 for the construction of rat PPARδ and
PPARγ. Both rat PPARδ and PPARγ exhibit high similarity
with human PPARδ (pdb id: 3GZ9; Connors et al., 2009) and
PPARγ (pdb id: 1ZGY; Li et al., 2005) with 91.8 and 98.5% of
similar identities, respectively. Therefore, these two structures
were chosen as templates for model building. Alignment of
the amino acids sequences into the abovementioned template
crystal structures were performed for both rat PPARδ and PPARγ
using the align2d function in EasyModeller 2.0 where 10 3D
models of each rat PPARδ and PPARγ were generated (Šali and
Blundell, 1993). This improved dynamic programming algorithm
was based on a variable gap penalty function that tends to place
gaps in solvent exposed and curved regions which decrease
the alignment error in standard alignment method. Generated
1www.ncbi.nlm.nih.gov
models were further improved through the loop modeling
followed by model optimization using the modified version of the
Beale restart conjugate gradients method. The model profile plots
were generated and analyzed. The lowest DOPE energy of the
loaded model was then taken into docking and MD simulation.
Molecular Docking
According to the study conducted by Wong and co-workers
(Fang et al., 2010), T3s could act as PPAR ligands possibly
due to partial structural similarity in comparison of a known
PPARγ agonist, troglitazone. Therefore, our group was interested
to look at the interactions between α- and δ- T3 and PPAR
receptors at atomic level. First the structures of α- and δ- T3 were
constructed and energy minimized using CHARMM force field
calculation implemented in Accelrys DISCOVERY STUDIO 3.1.
The ligands were docked to the plausible binding sites of PPARδ
and PPARγ homology models using the in-house CDOCKER
protocol. Different conformations were generated for each ligand
through high temperature molecular dynamics. The ligands were
heated to a temperature of 700 K in 2000 steps followed by
300 K cooling temperature. Then, the ligands were subjected
to refinement by grid-based (GRID 1) simulated annealing and
full force minimization after random rotation. The ligands were
allowed to flex while the protein homology models were held rigid
during refinement process. The generated ligand conformations
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FIGURE 4 | The relative gene expression level of INS1 in α-, γ-, and δ-tocotrienol treatment. (A) 2.8 mM glucose: 1p < 0.05 relative to negative control,
@p < 0.05 relative to positive control, #p < 0.05 relative to 1200 µM (same tocotrienol group). (B) 2.8 mM glucose and 30 mM KCl (calcium raising agent):
1p < 0.05 relative to negative control, @p < 0.05 relative to positive control, #p < 0.05 relative to 1200 µM (same tocotrienol group). (C) 16.7 mM glucose
(stimulant): all δ-T3 groups are 0.05 relative to negative control, 1p < 0.05 relative to negative control, #p < 0.05 relative to 1200 µM (same tocotrienol group),
∗p < 0.05 and ∗∗p < 0.01 relative to matched group. (D) 16.7 mM glucose and 30 mM KCl: 1p < 0.05 relative to negative control, #p < 0.05 relative to 1200 µM
(same tocotrienol group), ∗p < 0.05 relative to matched group.
were clustered according to their binding interactions. Finally,
the ligand conformation with the highest -CDOCKER interaction
energy and -CDOCKER energy was chosen for further analysis
and discussion.
Molecular Dynamics Simulation
Molecular dynamics simulation was performed with GROMACS
5.0.4 package, employing the GROMOS96 54a7 force field (Van
Der Spoel et al., 2005). Protonation states of ionizable residues
were chosen based on their most probable state at pH 7.4. The
ligand–protein complexes were energy relaxed using the steepest
descent energy minimization algorithm. The complexes were
then immersed in an octahedron-shaped box with the minimum
distance of 2 nm between the protein surface and the box walls.
The starting structures were solvated in simple point charge
(SPC) water. The system net charge was also neutralized by the
adding of Na+ counter ions which were randomly substituted
by water molecules. MD simulations were performed using the
LINCS algorithm (Hess, 2008) to constrain bond lengths and
periodic boundary conditions were applied in all directions.
Longrange electrostatic forces will be treated using the Fast
Particle-Mesh Ewald method (PME; Cerutti et al., 2009). Van der
Waals forces and Coulomb potential were treated using a cut-off
of 1.4 nm and the simulation time step was set to 2 fs. An initial
velocity obtained according to a Maxwell distribution at 300 K is
given to all the atoms. During the simulation, Berendsen barostat
and thermostat were set at 1 bar and 300 K with a coupling time of
τP = 2 ps and τT = 0.1 ps, respectively. The production run was
set for 10 ns at constant pressure and temperature conditions.
Statistical Analysis
Student’s paired t-test was used to determine the sample size and
the results obtained were collected from three samples. All the
data was analyzed using Statistical Package for Social Sciences
(SPSS, Inc., Chicago, IL, USA) version 17.0. Each treatment
group data was presented as mean ± standard error of mean
(SEM). The data were analyzed for normality test using Shapiro
Wilks statistic and one way analysis of variance (ANOVA)
was performed for multiple comparison between the treatment
groups with homogeneity test of variances using Tukey post hoc
test to determine significance difference (p < 0.05). p < 0.05 was
considered to be statistically significant. Student’s paired t-test
was used to analyze the comparison of insulin gene expression
levels of T3 at 150, 300, 600, and 1200 µM.
RESULTS
The cell viability test was carried out to assess the cytotoxicity
level of α-, γ-, and δ-T3 in the 1 h treatment at 150, 300, 600, and
1200 µM in glucose and KCl incubation mediums. All treated
cells were viable (>90%) after 1 h incubation (Table 2). In the
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FIGURE 5 | The relative gene expression level of GLUT2 in α-, γ-, and δ-tocotrienol treatment. (A) 2.8 mM glucose: 1p < 0.05 relative to negative control,
@p < 0.05 relative to positive control. (B) 2.8 mM glucose and 30 mM KCl (calcium raising agent): 1p < 0.05 relative to negative control, @p < 0.05 relative to
positive control. (C) 16.7 mM glucose (stimulant): 1p < 0.05 relative to negative control, #p < 0.05 relative to 1200 µM (same tocotrienol group), ∗p < 0.05 relative
to matched group. (D) 16.7 mM glucose and 30 mM KCl: 1p < 0.05 and 11p < 0.01 relative to negative control, @p < 0.05 relative to positive control, #p < 0.05
relative to 1200 µM (same tocotrienol group), ∗p < 0.05 relative to matched group.
quantitative analysis, data collected from qRT-PCR showed the
relative gene expression level of insulin secretion-associated gene,
the relationship between the ligand-modulated transcription
factors, insulin release gene and insulin gene transcription factor.
All the relative gene expressions in T3 treatments were presented
as (A) 2.8 mM glucose (basal), (B) 2.8 mM glucose and 30 mM
KCl (calcium raising agent), (C) 16.7 mM glucose (stimulant),
and (D) 16.7 mM glucose and 30 mM KCl after 1 h incubation
(20 islets per group; n = 3). Data were normalized to Actb,
compared to respective negative control (glucose and KCl buffer
only) and positive control (1 µM glyburide; One way ANNOVA
post hoc Tukey test). Data from qRT-PCR revealed that most of
the insulin secretion-associated genes, especially in the stimulant
group with KCl showed significantly higher expression in a dose
dependent manner when comparing within all four groups of δ-
and γ-T3. In contrast, most of the insulin secretion-associated
genes expression treated by α-T3 were not significantly affected.
Relative Gene Expression of
Ligand-Modulated Transcription Factor
PPARδ
The analysis of gene expression showed that PPARδ mRNA was
detected in all the groups of T3 treatments compared to the
negative control (Figure 2). Most of the gene expressions for the
T3 treatment groups remained unchanged with no significant
difference in the basal glucose conditions (Figures 2A,B). In
the stimulatory glucose conditions, the effect of α-T3 was
less significant whereas significantly higher expressions were
observed in δ- and γ-T3 in a dose dependent manner (Figure 2C).
All T3 treated groups showed significant increase in PPARδ
gene expression compared to the negative control. Significant
difference (p < 0.05) in PPARδ gene expression was observed at
300 and 600 µM when comparing α-T3 to δ-T3. δ-T3 showed
significantly more effective treatment (p < 0.05) than α-T3 in
up regulating the expression of PPARδ by 1.4 fold (p < 0.05) at
300 µM and by 1.3 fold (p < 0.05) at 600 µM. γ-T3 showed
significantly highest PPARδ expression than other T3 groups at
150 µM and significantly higher PPARδ expression as compared
to α-T3 at 1200 µM (1.5 fold; p < 0.05). In stimulatory glucose
with added KCl (Figure 2D), the PPARδ gene was expressed
significantly greater than the negative control in all four γ- and
δ-T3 groups (p< 0.05). However, only 600 and 1200 µM of α-T3
showed significant effect on the PPARδ expression compared to
the negative control. In δ-T3, a significantly higher expression
(p < 0.05) was observed at 1200 µM by 1.8 fold compared to
150 µM and by 1.7 fold compared to 300 µM in a dose dependent
manner. Whereas in γ-T3, a significantly higher expression was
observed at 1200 µM by 1.9 fold compared to 150 µM (p< 0.01),
by 1.5 fold compared to 300 µM (p < 0.05) and by 1.1 fold
compared to 600 µM (p < 0.05) in a dose dependent manner.
The higher concentration of δ- and γ-T3 (1200 µM) in both
stimulatory glucose groups also revealed up regulated PPARδ
expression comparable to the positive control.
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FIGURE 6 | The relative gene expression level of PDX1 in α-, γ-, and δ- tocotrienol treatment. (A) 2.8 mM glucose: all δ-T3 groups are 0.05 relative to
negative control, 1p < 0.05 relative to negative control, #p < 0.05 relative to 1200 µM (same tocotrienol group), ∗p < 0.05 relative to matched group. (B) 2.8 mM
glucose and 30 mM KCl (calcium raising agent): 1p < 0.05 relative to negative control, @p < 0.05 relative to positive control, #p < 0.05 relative to 1200 µM (same
tocotrienol group), ∗p < 0.05 relative to matched group. (C) 16.7 mM glucose (stimulant): 1p < 0.05 relative to negative control, @p < 0.05 relative to positive
control, ∗p < 0.05 relative to matched group. (D) 16.7 mM glucose and 30 mM KCl: 1p < 0.05 relative to negative control, @p < 0.05 relative to positive control,
#p < 0.05 relative to 1200 µM (same tocotrienol group), ∗p < 0.05 and ∗∗p < 0.01 relative to matched group.
PPARγ
Similarly, the data from basal glucose groups revealed that most
of the T3 groups showed significantly higher expression than
negative control, but no dose dependent increase of PPARγ
expression was observed indicating that all T3 groups had less
impact on PPARγ in both basal glucose groups with low glucose
as limiting factor. Only α- and δ-T3 revealed dose dependent
increase of PPARγ expression when comparing between 150 and
1200 µM (p < 0.05; Figure 3A). Whereas in the basal KCl
group (Figure 3B), all the T3 groups showed significantly higher
expression than the negative control, but no dose dependent
increase of PPARγ expression was observed indicating that KCl
did not give any impact on PPARγ in basal glucose condition.
The outcome suggested that in both basal glucose groups, low
glucose acted as a limiting factor to PPARγ gene expressions. In
the stimulatory glucose groups (Figures 3C,D), the expression
of PPARγ increased after 1 h of T3 treatment. However, α-T3
effect was inert compared to δ- and γ-T3. δ-T3 treatments
indicated a significant upregulated gene expression in a dose
dependent manner in stimulatory glucose conditions with a
significant PPARγ expression increase by 1.1 fold (p < 0.01)
compared to α- T3 at 300 µM and by 1.2 fold (p < 0.01)
compared to α-T3 at 600 µM (Figure 3C). While γ-T3 showed
a significantly higher gene expression by 1.3 fold (p < 0.05)
compared to α- T3 at 150 µM, 1.1 fold (p < 0.01) compared to
α-T3 at 300 mM and by 1.2 fold (p < 0.05) compared to α-T3 at
600 µM. The analysis of PPARγ gene expression in the stimulant
glucose with KCl group (Figure 3D) indicated that KCl further
enhanced the expression of PPARγ in δ-T3 stimulatory glucose
medium. In δ-T3 treated group, 600 and 1200 µM showed a
significant increase (p < 0.05) in expression compared to both
negative and positive controls. While γ-T3 treatment revealed
a significantly upregulated PPARγ gene expression compared
to both negative and positive control at 1200 µM (p < 0.05).
At 1200 µM, γ-T3 treatment also showed a significantly
upregulated PPARγ expression as compared to α-T3 (1.3 fold;
p < 0.05). No significant change was observed in the expression
of α-T3 treatment. In δ-T3 treatment, PPARγ expressed in a
dose dependent manner with a significant change observed at
1200 µM compared to 150 µM (by 1.4 fold; p < 0.05). δ-T3
treatment revealed a significantly higher expression by 1.2 fold
compared to γ- T3 (p < 0.05) at 300 µM and 1.3 fold compared
to α-T3 (p < 0.05) at 600 µM, respectively. γ-T3 treatments
indicated a significant upregulated gene expression in a dose
dependent manner in stimulatory glucose conditions (p < 0.05).
Whereas δ- T3 revealed the enhancement of the PPARγ gene
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FIGURE 7 | The relative gene expression level of MafA in α-, γ-, and δ-tocotrienol treatment. (A) 2.8 mM glucose: 1p < 0.05 relative to negative control,
∗p < 0.05 relative to matched group. (B) 2.8 mM glucose and 30 mM KCl (calcium raising agent): 1p < 0.05 relative to negative control, ∗p < 0.05 relative to
matched group. (C) 16.7 mM glucose (stimulant): all δ-T3 groups are 0.05 relative to negative control, 1p < 0.05 relative to negative control, #p < 0.05 relative to
1200 µM (same tocotrienol group), ∗p < 0.05 relative to matched group. (D) 16.7 mM glucose and 30 mM KCl: all δ-T3 groups are 0.05 relative to negative control,
1p < 0.05 relative to negative control, #p < 0.05 and ##p < 0.01 relative to 1200 µM (same tocotrienol group), ∗p < 0.05 relative to matched group.
FIGURE 8 | The relative gene expression level of BETA2 in α-, γ-, and δ-tocotrienol treatment. (A) 2.8 mM glucose: all δ-T3 groups are 0.05 relative to
negative control, 1p < 0.05 relative to negative control, ∗p < 0.05 relative to matched group. (B) 2.8 mM glucose and 30 mM KCl (calcium raising agent): 1p < 0.05
relative to negative control. (C) 16.7 mM glucose (stimulant): 1p < 0.05 relative to negative control, #p < 0.05 relative to 1200 µM (same tocotrienol group),
∗p < 0.05 relative to matched group. (D) 16.7 mM glucose and 30 mM KCl: 1p < 0.05 relative to negative control, @p < 0.05 relative to positive control, #p < 0.05
relative to 1200 µM (same tocotrienol group), ∗p < 0.05 relative to matched group.
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FIGURE 9 | RMSD plots of PPARδ backbone in complex with
α-tocotrienol (black line) and δ-tocotrienol (red line) as a function of
simulation time.
FIGURE 10 | RMSD plots of PPARγ backbone in complex with
α-tocotrienol (black line) and δ-tocotrienol (red line) as a function of
simulation time.
expression in the stimulatory glucose condition especially in the
presence of KCl compared to glyburide indicating that among all
three T3s, δ-T3 works most effectively with the presence of KCl
in stimulant glucose condition.
Relative Gene Expression of Insulin
Release Gene
INS1
The effects of T3s in basal glucose groups were minimal in the
INS1 gene expression; however, both α- and δ-T3 treatment
revealed a significantly higher INS1 expression than glyburide
at high dose of 1200 µM (Figure 4A). While at 600 µM of
basal glucose with KCl (Figure 4B), a significant increase of
γ-T3 was observed as compared to glyburide. In contrast to
basal glucose, stimulatory glucose group (Figure 4C) showed
better effect of T3 treatment in INS1 expression where all the
T3 treated groups upregulated INS1 gene expression in a dose
dependent manner in the sequence of effectiveness: α < γ < δ.
A significant increase in INS1 expression was observed with δ-T3
treatment at 1200µM compared to at 300µM (1.2 fold; p< 0.05).
δ-T3 showed significantly effective treatment than α-T3 in up
regulating the expression of INS 1 at 1200 µM with a significant
increase of 1.2 fold (p < 0.01) at δ- 1200 µM compared to α-T3
at 1200 µM. A similar effect was observed when KCl was added
into the stimulatory glucose group (Figure 4D). INS 1 gene was
expressed significantly higher than the negative control at α-T3
(1200µM) and γ-T3 (1200µM) only while all δ-T3 groups except
at 150 µM showed significantly higher INS expression compared
to the negative control. δ-T3 revealed significant increase in
INS1 expression at 1200 µM compared to 150 µM (twofold;
p < 0.05) in a dose dependent manner. At 600 µM, δ-T3
showed an increase of 1.3 fold gene expression compared to α-
and γ-T3 (p < 0.05). The analysis of gene expression showed
that glucose played an important role in T3 treated INS1 gene
expressions as there was no adverse effect of T3s on the gene
expressions in basal glucose groups but significant increase in
INS1 expression especially in δ-T3 when incubated in stimulatory
glucose condition. KCl in stimulatory glucose further potentiated
the effect of δ- T3 in INS1 gene expression.
GLUT2
The effect of T3s on GLUT2 gene expression was dependent on
the presence of high glucose especially with δ- T3 revealed a dose
dependent increase of GLUT2 expression but not α- T3. In basal
glucose (Figure 5A) and basal glucose with KCl (Figure 5B), the
data demonstrated that GLUT2 gene was only able to respond
to δ- and γ-T3 treatment in basal glucose or basal glucose with
KCl administration at 1200 µM. The effects of δ- and γ-T3
were enhanced in stimulatory glucose showing gradual increase
in GLUT2 expression. In stimulatory glucose group, δ-T3 at
1200 µM showed a significant higher gene expression compared
to the negative control and a 1.6 fold increase compared to
δ-T3 at 150 µM (p < 0.05). γ-T3 at 1200 µM also showed a
twofold increase in gene expression compared to γ-T3 at 150 µM
(p < 0.05) while no adverse effect of α-T3 was observed. At
300 µM, δ-T3 produced an increase of 1.8 fold gene expression
compared to γ- and α-T3 (p< 0.05; Figure 5C). In contrast, when
the stimulatory glucose incubation medium was added with KCl,
the effect of δ- T3 was augmented with all the δ-T3 treated groups
showing significantly higher GLUT2 expression compared to
the negative control. T3 facilitated the uptake of glucose into β
cell with the presence of KCl by further boosted the effect of
δ- and γ-T3 on GLUT2 gene expression in a dose dependent
manner and better expression compared to α-T3 (Figure 5D). At
1200 µM, both δ- and γ-T3 revealed significantly higher GLUT2
expression than both negative control and glyburide (p < 0.05).
δ-T3 enhanced a twofold higher GLUT2 expression compared to
δ-T3 at 150 µM (p < 0.05) and 1.5 fold greater gene expression
compared to δ- T3 at 300 µM (p < 0.05), respectively. δ-T3 also
presented significantly higher GLUT2 expression than α-T3 at
150 µM (1.5 fold; p < 0.05), 300 µM (twofold; p < 0.05) and
1200 µM (1.8 fold; p < 0.05), respectively. As comparing δ-T3
to γ-T3, significantly higher GLUT2 expression was observed at
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FIGURE 11 | Hydrogen bond plots between PPARδ residues and α-tocotrienol (black line) and δ-tocotrienol (red line) during the final 5 ns of
simulation.
150 µM (1.5 fold; p< 0.05), 300 µM (1.9 fold; p< 0.05), 600 µM
(1.8 fold; p< 0.05) and 1200 µM (1.4 fold; p< 0.05), respectively.
The data demonstrated the synergistic activation of INS1 and
GLUT2 gene expressions by δ- and γ-T3 treatments.
Relative Gene Expression of Insulin Gene
Transcription Factor
PDX1
Based on the result of PDX1 gene expression, the effects of all
three T3s were comparable with minimal effects on the PDX1
gene activation in basal glucose group. However, all three T3
were able to boost the gene expression at 600 and 1200 µM
higher than the negative control (p < 0.05). Only α- and δ-T3
showed a significant increase of PDX1 gene expression in a dose
dependent manner (p < 0.05). At 300 µM, δ-T3 exhibited 1.4
fold higher PDX1 expression compared to γ-T3 (Figure 6A).
On the other hand, only δ-T3 showed greater treatment with
up regulated gene expression than glyburide at 1200 µM with
the addition of KCl (Figure 6B). Similar result was reported,
indicating the less effectiveness of KCl role in basal glucose.
While the effect of α-T3 was not as noble as δ- and γ-T3, both
δ- and γ-T3 demonstrated strong stimulatory effect at 600 and
1200 µM with significantly higher PDX1 expression compared
to glyburide in the stimulatory glucose condition (Figure 6C).
At 600 and 1200 µM, δ-T3 showed significant greater gene
expression compared to both negative and positive controls as
well as to α- and γ-T3. At 600 µM, PDX1 expression at δ-T3
was increased to 1.5 fold compared to α-T3 (p < 0.05) and 1.3
fold compared to γ-T3 (p< 0.05). At 1200 µM, PDX1 expression
in δ- T3 revealed 1.3 fold higher than α-T3 (p < 0.05) and 1.6
fold higher than γ-T3 (p < 0.05), respectively. The presence of
KCl in the stimulatory glucose condition further enhanced the
effect of δ-T3 in PDX1 expression in a dose dependent manner
with a significantly higher expression compared to glyburide
at 1200 µM (p < 0.05; Figure 6D). Significantly higher PDX1
gene expression was observed in all δ-T3 groups except at
150 µM when compared to the negative control (p < 0.05).
A dose dependent increase in expression was observed in δ-T3
group (p < 0.05) where at 1200 µM it showed 1.8 and 1.5
fold increase compared to 150 and 300 µM, respectively. At
1200 µM, δ-T3 yielded a greater PDX1 activation compared
to glyburide. For γ-T3, 600 and 1200 µM treatment produced
significantly higher PDX1 expression compared to the negative
control, while only α-T3 at 1200 µM revealed significantly higher
PDX1 expression compared to the negative control. δ-T3 showed
significantly effective treatment than α-T3 in up regulating the
expression of PDX1 at 300 and 1200 µM. PDX1 expression
was upregulated significantly in δ-T3 at 300 µM by 1.5 fold
(p < 0.01) compared to α-T3 at 300 µM and 1.6 fold increase
in δ-T3 at 1200 µM compared to α-T3 at 1200 µM (p < 0.05).
At 300 µM, δ- T3 was found significantly better in upregulating
PDX1 expression by 1.2 fold as compared to γ-T3 (p < 0.05).
The strong stimulatory effect of δ-T3 in PDX1 gene activation
was observed in basal and stimulant glucose condition. In
contrast, the effect of α- and γ-T3 was not as noble as δ-T3.
The effect of δ-T3 was greater than glyburide in high glucose
as well as in high glucose with KCl suggesting KCl enhanced
the effect of δ-T3 in PDX1 expression in a dose dependent
manner.
MafA
Similar to PDX1, all T3s displayed minimal effect on MafA
gene expression in the basal 2.8 mM glucose group (Figure 7A)
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FIGURE 12 | Hydrogen bond plots between PPARγ residues and α-tocotrienol (black line) and δ-tocotrienol (red line) during the final 5 ns of
simulation.
and basal with KCl group (Figure 7B) indicated the less
effectiveness of KCl role in basal glucose. In contrast, δ- T3
had proven a significantly better treatment than γ- and α-T3 in
the stimulatory glucose condition (Figure 7C). δ-T3 treatment
revealed a significant improved of MafA expression with all four
δ-T3 groups showed significant increase in expression compared
to negative control (p < 0.05). However, only 600 µM of
α -T3 and 1200 µM of γ-T3 presented a stimulatory effect
on MafA expression with significant higher gene expression
than the negative control (p < 0.05). δ-T3 was proven a
better treatment than α-T3 at 150 and 600 µM: increased
MafA expression by 1.5 fold at δ-T3, 150 µM (p < 0.05)
and 1.3 fold at δ-T3, 600 µM (p < 0.05) compared to α-T3,
respectively. While significantly higher MafA expression of δ-T3
were observed at 150 µM (1.2 fold; p < 0.05) and 300 µM
(1.4 fold; p < 0.05) when compared to γ-T3. Moreover, both
δ- and γ-T3 revealed better potency than α-T3 on MafA
expression in the presence of KCl (Figure 7D). The addition
of KCl in the incubation medium further enhanced the effect
of δ- and γ-T3 in a dose dependent manner. δ-T3 treatment
groups showed significant increase of MafA expression than the
negative control (p < 0.05), The highest MafA gene expression
in δ-T3 was observed at 1200 µM with significantly higher
expression than at 150 µM (1.6 fold; p < 0.01), 300 µM (1.5
fold; p < 0.05) and 600 µM (1.3 fold; p < 0.05), respectively.
Comparison between the effect of δ-T3 and α-T3 on MafA
expression showed significant difference in gene expression
at 150 µM (1.4 fold; p < 0.05) and 1200 µM (1.5 fold;
p< 0.05), while the adverse effect of δ-T3 was also observed when
compared to γ-T3. All four δ-T3 groups revealed significantly
higher MafA expression compared to γ-T3 at 150 µM (1.3
fold; p < 0.05), 300 µM (1.2 fold; p < 0.05), 600 µM
(1.3 fold; p < 0.05), and 1200 µM (1.2 fold; p < 0.05),
respectively. δ-T3 possessed a better potency than α- and
γ-T3 on MafA expression in the presence of high glucose
concentration.
BETA2
The analysis of BETA2 gene expression showed that δ-T3
provided a better effect on gene expression compared to α-T3
in basal glucose incubation medium (Figure 8A). At 150 and
1200 µM, δ-T3 revealed a significant higher gene expression
compared to α-T3 (p < 0.05): by 1.4 fold at 150 µM and
by 1.6 fold at 1200 µM. However, the addition of KCl did
not give a great impact on BETA2 gene expression as no
activation of BETA2 expression was observed in α-T3 while
Frontiers in Pharmacology | www.frontiersin.org 12 August 2016 | Volume 7 | Article 291
fphar-07-00291 August 27, 2016 Time: 12:1 # 13
Chia et al. Tocotrienols on Insulin Genes Expression
FIGURE 13 | MD simulation snapshots of δ-tocotrienol and α-tocotrienol complexed with rat PPARδ. The atom coloring for δ-tocotrienol and α-tocotrienol
are as follows: carbon in gray, oxygen in red, nitrogen in blue, sulfur in yellow, and hydrogen in white. The surface is colored by the hydrophobicity of the protein
residues, from blue for hydrophilic to brown for hydrophobic.
only 600 and 1200 µM of both γ- and δ-T3 as well as
γ-T3 at 300 µM showed significantly higher gene expression
compared to the negative control (p < 0.05; Figure 8B).
In contrast, the effect of δ-T3 was boosted in stimulatory
glucose condition showing a significantly higher gene expression
than α-T3 in a dose dependent manner (Figure 8C). While
both δ- and γ-T3 activated BETA2 expression in stimulatory
glucose condition with KCl. γ-T3 also showed significantly
higher gene expression than the negative control at 600–
1200 µM (p < 0.05) while only δ-T3 at 300 µM revealed a
significantly higher BETA2 expression as compared to α-T3 at
300 µM (p < 0.05). In contrast, both δ- and γ-T3 activated
BETA2 expression in stimulatory glucose condition with KCl
(Figure 8D). At 1200 µM, γ-T3 significantly upregulated the
expression of BETA2 as compared to both negative and positive
controls (p < 0.05) as well as α-T3 (1.7 fold; p < 0.05). At
600 µM, δ-T3 showed a significant higher gene expression
when compared to the positive control (p < 0.05), α-T3
(1.8 fold; p < 0.05) and γ-T3 (1.2 fold; p < 0.05). The
study revealed that KCl had effectively enhanced the effect of
δ-T3 at lower dosage (600 µM) and γ- T3 at higher dosage
(1200 µM) with significantly higher expression of BETA2 than
glyburide.
DISCUSSION
From the analysis of our findings, this study showed
pharmacological activation of PPARδ and PPARγ by T3s (δ- and
γ-T3) especially in the presence of high glucose concentration.
PPARγ has been identified as the receptor for thiazolidinedione,
an oral antidiabetic drug (Rosen et al., 2003) while there is no
report of the PPARδ involvement with current antidiabetic drug
yet. Nonetheless, it functions as transcriptional regulator for
glucose homeostasis and lipid metabolism which is proven to
act as a lipid sensor and is a potential therapeutic target to treat
metabolic disease (Reilly and Lee, 2008) and regulated glucose
metabolism and insulin sensitivity (Lee et al., 2006). However,
the outcome from molecular docking revealed the minimal
chance of direct interaction between these T3 derivatives and
the ligand-modulated transcription factors. Together with the
RTPCR analysis, it appears that the activation of PPARδ and
PPARγ in parallel with other insulin genes transcription is able
to regulate preproinsulin mRNA levels. Based on our findings,
glyburide in contrast did not give great impact on glucose-
stimulated proinsulin biosynthesis or preproinsulin mRNA
levels although it is able to stimulated insulin secretion at both
basal and stimulatory glucose concentrations, which is consistent
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FIGURE 14 | MD simulation snapshots of δ-tocotrienol and α-tocotrienol complexed with rat PPARγ. See Figure 13 for legend.
with the result from previous studies (Levy and Malaisse, 1975;
Wicksteed et al., 2003).
The smallest molecule of δ-T3 with greatest mobility and
agility enabled a better penetration and interaction with β cell,
as supported by Vignini et al. (2011). α-T3 on the other hand, is
the least active form among all the T3 derivatives. The presence
of KCl in the culture further increased the depolarization of
the β cell membrane (Ren et al., 2007), facilitating the intake
of glucose and T3 derivatives into the cells. This explains the
better bioactivity of δ -T3 not only in the activation of PPARs,
but also in the upregulation of other insulin secretion-associated
gene expression levels. Together with previous findings, the
high levels of T3s found in golgi apparatus and endoplasmic
reticulum suggested that the ability of T3s to enhance the
synthesis of preproinsulin in the endoplasmic reticulum and
assisted the transport of proinsulin through golgi apparatus
in the insulin synthesis and secretion process (Drevon, 1991;
Ren et al., 2007). This finding supports the outcome of the up
regulated gene expression level of PPARδ and PPARγ by δ- and
γ-T3 in the stimulatory glucose groups but not α-T3 due to
the unresponsiveness in the activation of PPARγ in stimulatory
glucose groups. The upregulation in the PPARδ and PPARγ
gene expression suggested that δ- and γ-T3 targeted at the same
receptor which involve in the same mechanism in controlling
glucose homeostasis. Nevertheless, further investigation such as
luciferase assay needs to be carried out to identify the pathways
involved.
To gain insights on how α- and δ-T3 could bind to
rat PPARδ and PPARγ receptors, homology models were
built from the crystal structures of human PPARδ (PDB id:
3GZ9) and PPARγ (PDB id: 1ZGY). These two T3s were
specifically chosen for the docking study based on their effects
on relative gene expression of ligand-modulated transcription
factor level and other reported work (Fang et al., 2010). The
compounds were docked to the plausible binding sites of the
models as suggested by some of the literature reviews (Fratev
et al., 2015; Maltarollo et al., 2015). First, the cDOCKER
program generated more than 100 binding poses. To choose
the best conformation, the protein–ligand binding interactions
were visually inspected followed by ranking them according
to their binding interaction energies and clustered according
to their binding conformations. The best ligand–protein
complexes were subjected to molecular dynamics simulation
using GROMACS 5.0.4. As shown in Figures 9 and 10, all
protein–ligand complexes reached equilibrium state after 10
ns of simulation as shown in the RMSD plots of the protein
backbone of PPARδ and PPARγ in complex with α- and δ-T3.
There was no major fluctuation in both the RMSD of PPARs
backbone during the course of 10 ns simulation suggesting
that the binding of α- and δ-T3 did not induce any major
changes to the protein conformation. In term of H-bonding
interaction, δ-T3 showed higher affinity to form H-bonding
interaction with His412 compared to α-T3 which recorded only
a single interaction with PPARδ during the course of simulation
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(Figure 11). This could be the key reason why δ-T3 could
activate PPARδ but not α-T3 as reported by Wong and co-
workers (Fang et al., 2010). Future development of δ-T3 into a
potent PPARδ agonist should focus on this region of interest.
On the other hand, δ-T3 could form three H-bonds with His294,
Ser370 and Gln373 residues of PPARγ while α-T3 predominantly
engaged with Arg308 (Figure 12). Figures 13 and 14 summarize
the overall non-polar interactions of δ-T3 and α-T3 with the
residues in rat PPARδ and PPARγ during the final 5 ns of
simulations.
The significantly higher INS1 gene expression in the
stimulatory glucose groups showed that δ-T3 was able to enhance
preproinulin mRNA synthesis level while γ- and α-T3 showed
less impact on the transcriptional level. Metabolic regulation
of insulin gene expression by δ-T3 enabled the maintenance of
sufficient intracellular insulin in β-cell to sustain the secretory
demand in high glucose condition (Poitout et al., 2006).
Short-term regulation of insulin biosynthesis transcription and
translation level as reported by Leibiger et al. (1998) supported
our outcome where a short term exposure of isolated pancreatic
islets to stimulatory glucose (16.7 mM) resulted in a 2- to 5-
fold elevation in (prepro)insulin mRNA levels within 60–90 min.
This finding is further supported by the short half-life and rapid
turnover of T3 derivatives, by Yap et al. (2003). The cell culture
microenvironment provided by the microfluidic device further
enhanced the lifespan of the β cells and consistencies of the
treatment throughout the 1 h treatment (Hung et al., 2005).
PPARγ has also been reported to significantly activate GLUT2 in
the rat β cells (Higa et al., 1999) supporting GLUT2 expression
in parallel with this enhanced response. δ- T3 activated GLUT2
in stimulatory glucose condition and further improved by the
administration of KCl, which in turn enhanced glucose entrance
into β cells (Vaulont et al., 2000). The synergistic effects of both
INS1 and GLUT2 gene in δ- and γ-T3 treatment revealed that
glucose played a major role in the gene expression despite of the
effectiveness of the T3.
PDX1 is the most important insulin transcription factor
in glucose-stimulated insulin gene transcription and is only
expressed in pancreatic β cell (Ren et al., 2007). From our
findings, δ-T3 was able to upregulate the expression level of PDX1
to about twofold in both basal and stimulatory glucose groups
with added KCl at 1200 µM compared to the negative control,
where similar research outcome has been reported by Mosley and
Ozcan (2004). A significantly upregulated expression of MafA
in both stimulatory glucose as well as stimulatory glucose with
KCl group in δ- and γ-T3 showed that exposure of β cells to
both glucose stimulant group had significantly increased MafA
mRNA expression which is also supported by Hagman et al.
(2005). Moreover, both δ- and γ-T3 displayed dose dependent
manner that possessed better potencies than α-T3 on MafA
expression in the presence of KCl. The similarity on the effects
of each T3 derivatives on these insulin gene transcription factors
(PDX1, MafA, and BETA2) showed the synergistic effect of these
genes in insulin transcription and mechanism (Zhang et al.,
2005).
While α-T3 and glyburide exert no activating effect, a
significantly upregulated BETA2 gene expression was observed
at δ-T3 (600 µM) and γ-T3 (1200 µM) in stimulatory glucose
group with added KCl compared to glyburide strongly supported
the effect of δ- and γ-T3 in the regulation of insulin gene
expression. MafA activates PDX1 and BETA2 in established
mechanism in glucose-stimulated insulin secretion pathway (Ren
et al., 2007). Interestingly, the upregulated gene expression of
MafA, PDX1, and BETA2 by δ- and γ-T3 at stimulatory glucose
condition and added KCl confirmed the effects of both T3
derivatives in the enhancement of targeted activation of insulin
gene transcription. The effects of δ-T3 in stimulatory glucose
with KCl are confirmed with statistically significant of PPARγ,
GLUT2, PDX1, and BETA2 gene expression levels compared
to glyburide. δ-T3 was able to enhance insulin synthesis in
response to glucose and KCl whereas α- and γ-T3 having less
potency than δ-T3 at similar concentrations. Therefore, the
overall results suggest that δ-T3 exhibited a greatest potency in
the activation of the insulin transcriptional factors. Since the
targeted pancreatic β cell involved in the insulin synthesis are
responsible for relative deficiency of insulin secretion that leads
to type 2 diabetes mellitus, the findings of the study have provided
the important role of δ-, γ-, and α-T3 in the prevention of
hyperglycemia as well as the medical management of glucose
homeostasis.
CONCLUSION
In summary, we have discovered the essential role of δ-, γ-,
and α-T3 in the mechanisms to enhance insulin release through
activation of insulin secretion-associated genes expression. The
study was conducted in the microfluidic device which was able
to provide a continuous supply of nutrient and maintenance
of the accuracy of tocotrienol dosage throughout the treatment.
The outcome could have given a remarkable impact on
the cell culture research. The gene expression analysis in
tocotrienol treatments suggested an important role of tocotrienol
derivatives in the activation of insulin transcription factors
following an impact on insulin secretion. Apart from the
effectiveness of tocotrienols, glucose played a major role in
the gene expression study where most of the insulin secretion
associated genes were expressed depending on the presence
of high glucose (16.7 mM). In addition, δ-T3 revealed the
greatest impact on insulin synthesis level in the glucose-
stimulated insulin secretion pathway than γ- and α-T3. δ-T3
together with the presence of membrane depolarising agent,
KCl in the stimulatory glucose cell culture induced greatest
insulin synthesis suggesting a synergistic effect of δ-T3 and
KCl in the regulation of insulin gene transcriptional level in
the hyperglycemic condition. Our discovery has also provided
new prospects for the medical management of hyperglycemia
and glucose homeostasis associated with type 2 diabetes
mellitus.
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